What is ACE-031?
A soluble activin type IIB receptor fusion protein that soaks up myostatin; a Duchenne trial was stopped for bleeding-related side effects.
ACE-031 in the library · · Human Trials · What are peptides?
4 registered trials · 2 indexed papers · 1 human / 0 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
ACE-031 is described as an engineered protein (the activin receptor IIB fused to an antibody Fc region) that traps myostatin and related signals, developed by Acceleron.
Mechanism (as described)
- By blocking ActRIIB ligands it increases muscle mass in animals and in a primate study (Cadena et al., 2026).
Evidence (as described)
- Black-market products have been analyzed by anti-doping labs (Reichel et al., 2025).
Status
Development discontinued; banned in sport.
Registered human trials (4)
| Trial | Phase | Status | Year | Enrolled |
|---|---|---|---|---|
| Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | Phase 2 | terminated | 2010 | 24 |
| Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | Phase 2 | terminated | 2010 | 11 |
| A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women | Phase 1 | completed | 2009 | 70 |
| A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers | Phase 1 | completed | 2008 | 48 |
Peer-reviewed studies (2)
| Paper | Authors | Journal | Year | Type |
|---|---|---|---|---|
| Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial | Campbell C et al. | Muscle & nerve | 2017 | Randomized Controlled Trial |
| A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers | Attie KM et al. | Muscle & nerve | 2013 | Randomized Controlled Trial |
Conditions researched
Related compounds
- Bimagrumab
- Follistatin-344
- Anamorelin (non-peptide)
- IGF-1 LR3
- Octreotide
- ACTH (Corticotropin)
- Angiotensin II
- Apelin
- BNP (Nesiritide)
- CJC-1295 (no DAC), Mod GRF 1-29
FAQ
What is ACE-031?
A soluble activin type IIB receptor fusion protein that soaks up myostatin; a Duchenne trial was stopped for bleeding-related side effects.
How many registered human trials study ACE-031?
The PeptideWhiz trial index lists 4 registered trials for ACE-031, the most recent from 2010.
How much published research exists on ACE-031?
The PeptideWhiz paper index links 2 PubMed papers to ACE-031; by study type, 1 human and 0 animal studies.
Which conditions is ACE-031 researched for?
Muscle gain, sarcopenia & building muscle after 40, Muscle disease (myopathy).
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).